Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM109626-01A1
Agency Tracking Number: R41GM109626
Amount: $640,986.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA11-214
Timeline
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-25
Award End Date (Contract End Date): 2016-08-31
Small Business Information
3495 Kent Ave, Suite E400, West Lafayette, IN, 47906-4182
DUNS: 965433258
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 WEIGUO TAO
 (765) 494-9605
 watao@purdue.edu
Business Contact
 ANTON ILIUK
Phone: (765) 490-6834
Email: anton.iliuk@tymora-analytical.com
Research Institution
 PURDUE UNIVERSITY
 155 S GRANT STREET
WEST LAFAYETTE, IN, 47907-2114
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations Vast majority of plasma serum proteomic strategies lack adequate reproducibility sensitivity and robustness for clinical tests Solutions for these serious technological barriers to develop a reliable detection platform toward clinical implementation are elusive In this NIH STTR Phase I study we will develop a novel analytical platform based on functionalized soluble nanopolymers into commercial products for simple routine serum plasma biomarker discovery Through this STTR Phase I project we will leap from our expertise in pioneering the application of soluble nanopolymers to establish Polymer based Metal Ion Affinity Capture PolyMAC functionalized with different metal ions as a powerful platform for sequential depletion of high abundant proteins and isolation of low abundant plasma proteins to achieve sensitive reproducible and quantitative plasma proteomics In particular we will validate the platform through analyzing plasma samples including those from Ossabaw swine a distinctive large animal model for early detection of coronary artery disease CAD In order to achieve these goals the following aims will be completed Aim Optimization of PolyMAC Cu for high abundant plasma protein depletion Aim Optimization of in depth plasma proteome analyses using sequential PolyMAC M isolations By the completion of STTR Phase I studies we expect to develop a versatile sample preparation platform with core reagents and kits for plasma proteomics and to facilitate translating proteomics discovery to clinical applications PUBLIC HEALTH RELEVANCE Discovery of clinically useful biomarkers can offer enormous potential for modern medicine by providing earlier and better disease diagnosis improved prognosis for patient monitoring and preventative screening that can identify patients at highest risk This NIH STTR will support an effort to develop an innovative technology into commercial products that equip researchers with powerful tools and new directions in biomarker discovery field

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government